AIM
AIM ImmunoTech Inc. (AIM) Risks & Opportunities Analysis (2026)
No material changes this month.
Risks
Negative interest coverage versus profitable peers increases refinancing sensitivity and can constrain flexibility if rates stay elevated or earnings soften.
Low net debt to EBITDA versus peers limits balance-sheet stress, but the negative coverage profile still leaves AIM more exposed to earnings volatility than stronger operators.
An extreme cash conversion cycle driven by very high payables can support liquidity, yet it also signals working-capital dependence that peers with steadier cash generation avoid.
Current and quick ratios above 2.0 indicate near-term liquidity strength, reducing default risk relative to leveraged peers and partially offsetting the earnings-coverage weakness.
Opportunities
Net debt to EBITDA below 0.5x gives AIM more financial headroom than many peers, supporting resilience if demand or margins improve.
Strong current and quick ratios above 2.0 position AIM better than tighter-liquidity peers to absorb working-capital swings and fund near-term growth.
Very high payables-driven cash conversion can preserve cash versus peers, creating operating flexibility if supplier terms remain stable and volumes hold.
Low leverage combined with liquidity strength improves AIM’s ability to benefit from any sector recovery faster than more indebted competitors.
Overall Score
AIM’s low leverage and strong liquidity support positioning versus peers, but negative interest coverage and working-capital dependence keep the forward risk profile only moderately favorable.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on AIM ImmunoTech Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
